Cromolyn sodium and masitinib combination inhibits fibroblast-myofibroblast transition and exerts additive cell-protective and antioxidant effects in a bleomycin-induced in vitro fibrosis model
Abstract:Background: Several in vitro and in vivo studies suggest that tyrosine kinase inhibitors may be effective in the treatment of idiopathic pulmonary fibrosis. In our previous study, we reported that combined treatment with masitinib, a tyrosine kinase inhibitor used to treat mastocytoma, and cromolyn sodium, a mast cell stabilizer drug used in allergic diseases, exerts synergistic cell-protective and antioxidant effects on an in vitro neurodegenerative model. In this study, we aimed to investigate the anti-fibro… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.